Written by the Nuvirox Research Team
Key points
- High LDL means more cholesterol is being carried in LDL particles, the main lipoproteins that deposit cholesterol in artery walls. Genetic, observational, and trial evidence agree that LDL is a cause of atherosclerotic heart disease, not just a marker.
- What counts as “too high” depends on your overall risk. The 2026 ACC/AHA guideline sets LDL goals by risk category, and an untreated LDL of 190 mg/dL or more is its own category that calls for a look at familial hypercholesterolemia.
- A single number is a starting point. Calculated LDL can be off when triglycerides are high, and apoB, non-HDL cholesterol, and lipoprotein(a) can add context.
Short answer: high LDL means your blood is carrying more cholesterol in low-density lipoprotein particles than is ideal for your arteries, and over years that raises the risk of plaque buildup, heart attack, and stroke. How worried to be depends on the number, how long it has been high, and the rest of your risk profile: age, blood pressure, smoking, diabetes, kidney function, and family history. A result of 190 mg/dL or higher is its own conversation, because it can reflect an inherited condition.
What is LDL cholesterol, exactly?
LDL cholesterol (LDL-C) is the amount of cholesterol carried inside low-density lipoprotein particles. Cholesterol doesn't dissolve in blood, so it travels in lipoproteins. Each LDL particle carries one apolipoprotein B (apoB) protein, which lets cells take the particle up through LDL receptors.
The trouble starts when there are too many of these particles for too long. LDL and other apoB-carrying particles are small enough to cross into the artery wall. Once there, some get stuck, and retained particles set off the slow inflammatory process that becomes plaque. A European Atherosclerosis Society (EAS) consensus panel reviewed more than 200 cohort studies, Mendelian randomization studies, and randomized trials, covering over 2 million people. It concluded that the evidence “unequivocally establishes that LDL causes” atherosclerotic cardiovascular disease (ASCVD), and that the effect grows with longer exposure.1
What LDL level counts as high?
There isn't one cutoff for everyone. Lab reports often flag anything above about 100 mg/dL, but current US guidance sets goals by risk. The 2026 ACC/AHA dyslipidemia guideline replaced the 2018 cholesterol guideline.7 It brought back numeric LDL-C and non-HDL-C goals, set according to 10-year risk from the new PREVENT calculator.
| Situation | LDL-C goal or flag | Notes |
|---|---|---|
| Borderline (3–5%) or intermediate (5–10%) 10-year risk | Below 100 mg/dL | Non-HDL-C goal below 130 mg/dL (2026 guideline) |
| High risk (≥10% 10-year risk) | Below 70 mg/dL | Non-HDL-C goal below 100 mg/dL (2026 guideline) |
| Established heart or vascular disease | Below 70 mg/dL; below 55 mg/dL if very high risk | Per published guideline summaries |
| Young adults with LDL-C ≥160 mg/dL | Consider medication early | Lifetime exposure matters |
| Untreated LDL-C ≥190 mg/dL | Severe hypercholesterolemia | 2018 guideline: high-intensity statin without a risk calculation; evaluate for FH |
What causes high LDL?
Usually it's genetics plus lifestyle, but some causes are worth ruling out because they're treatable on their own.
- Diet. Saturated fat (fatty meats, butter, full-fat dairy, coconut and palm oil) and trans fats raise LDL-C. Excess weight and inactivity add to the effect.
- Genetics, including familial hypercholesterolemia (FH). Variants in genes such as LDLR, APOB, and PCSK9 reduce LDL clearance. In a sequencing study of more than 26,000 people, about 7% of adults had LDL-C of 190 mg/dL or more. Fewer than 2% of that group carried a known FH mutation, but carriers had much higher coronary risk at any given LDL level.3
- Underactive thyroid. Hypothyroidism slows LDL clearance and is a classic secondary cause, which is why many clinicians check TSH when LDL is unexpectedly high.
- Menopause. LDL-C often rises across the menopausal transition as estrogen falls, sometimes enough to change a woman's risk category.
- Other conditions and medications. Diabetes, metabolic syndrome, kidney disease (especially nephrotic syndrome), some liver conditions, and certain medicines can push LDL up. Bring your medication list to the appointment.
LDL vs. non-HDL vs. apoB: which number matters most?
LDL-C is the standard measure, but it isn't the only atherogenic number on your panel, and sometimes it isn't the most informative one.
Non-HDL cholesterol is total cholesterol minus HDL. It captures cholesterol in every apoB-containing particle, including triglyceride-rich remnants, and is now a formal treatment goal.7 ApoB counts the particles directly, one apoB per particle. That matters when LDL-C and particle number disagree, which is common with insulin resistance and high triglycerides. The 2026 guideline says clinicians can consider apoB to assess residual risk, and can consider stepping up treatment if apoB stays elevated even when LDL-C is at goal. HDL is a separate measure with its own story; see what a low HDL result means.
What the studies actually show
Genetics, cohorts, and trials point the same way. The 2017 EAS consensus pooled meta-analyses covering more than 2 million participants, more than 20 million person-years of follow-up, and over 150,000 cardiovascular events. It found a consistent, dose-dependent, log-linear link between LDL-C exposure and ASCVD risk. The effect appeared to grow with longer exposure, which is what Mendelian randomization (nature's lifelong “trial” of LDL-lowering gene variants) would predict.1
Lowering LDL lowers events. The Cholesterol Treatment Trialists' meta-analysis used individual data from about 170,000 participants in 26 randomized statin trials, with roughly five years of median follow-up. Each 1.0 mmol/L (about 39 mg/dL) reduction in LDL-C cut major vascular events by about 22% (rate ratio 0.78) and all-cause mortality by 10%. No lower threshold appeared within the range studied, and the benefit held even in people who started below 2 mmol/L.2
High LDL matters even when short-term risk looks low. In the Cooper Center Longitudinal Study, 36,375 adults (median age 42) classified as low 10-year risk were followed for a median of 26.8 years. After adjustment for other risk factors, LDL-C of 160–189 mg/dL and of 190 mg/dL or more were independently associated with about 50–80% higher relative risk of cardiovascular death compared with LDL-C below 100 mg/dL.4 This is observational, but it fits the cumulative-exposure model.
The counterweight: the number on your report may not be exact. Most labs calculate LDL-C with the Friedewald equation, which assumes a fixed ratio between triglycerides and VLDL cholesterol. A study of 1.35 million lipid profiles found that this assumption breaks down. When triglycerides were 200–399 mg/dL and calculated LDL-C was below 70 mg/dL, Friedewald was correct only about 40% of the time, compared with 84% for the Martin/Hopkins method, which uses an adjustable factor.5 The CTT data also have limits: per mmol/L of lowering, statins didn't significantly reduce deaths from stroke or other vascular causes, and the absolute benefit for any one person depends on their baseline risk. A 22% relative reduction is a lot for someone at high risk and far less for someone at very low risk.2
When should you see a doctor about high LDL?
Any lipid result should be reviewed with your clinician, and some patterns make that more urgent. See a doctor promptly if:
- Your untreated LDL-C is 190 mg/dL or higher. The 2018 ACC/AHA guideline recommended high-intensity statin therapy at this level without needing a 10-year risk calculation,6 and an evaluation for familial hypercholesterolemia is reasonable. FH affects relatives too, so family testing matters.
- You have a parent or sibling who had a heart attack or stroke at a young age, or relatives with very high cholesterol.
- Your LDL jumped without an obvious reason, or you have diabetes, kidney disease, high blood pressure, or smoke.
Chest pain, pressure, or shortness of breath with exertion is not a lab question. Get urgent medical care.
What to do after a high LDL result
Start by confirming the number. Ask whether your lab uses the Friedewald or a newer equation, especially if your triglycerides were high. Repeat the test if the result doesn't fit your history. Ask about non-HDL-C and apoB, and if you've never had it measured, ask about a one-time lipoprotein(a) test. Lp(a) is genetically set, LDL-lowering diets don't touch it, and it changes how an LDL result should be read.
Lifestyle changes help: swap saturated fat for unsaturated fats, add soluble fiber (oats, beans, psyllium), and lose excess weight if you need to. They can be enough at borderline levels, but they're rarely enough on their own at 190 mg/dL or higher. If medication comes up, side effects are a fair question, and our review of whether statins cause fatigue goes through what the blinded trials show. Recheck lipids 4–12 weeks after any change so you know whether it worked.
Frequently asked questions
Is an LDL of 130 bad?
It's above the 2026 guideline goal for adults at borderline or higher risk, but it isn't an emergency on its own. It's a good reason to work out your 10- and 30-year risk with your clinician.
Can you have high LDL and still be healthy?
Most people with high LDL feel fine, because plaque builds silently for decades. Long-term data link LDL-C of 160 mg/dL or more to higher cardiovascular mortality even when 10-year risk looks low.
Why is my LDL high when I eat healthy?
Genetics sets much of your LDL level, and inherited high LDL can persist despite a good diet. Hypothyroidism, menopause, and some medications are other common reasons, so a workup beats dietary self-blame.
Should I worry about LDL if my HDL is high?
Yes. A high HDL doesn't cancel out a high LDL, and the evidence that lowering LDL reduces events is far stronger than any evidence for HDL. Treat them as separate pieces of information.
A note before any supplement: An LDL result is something for your clinician to interpret alongside your full risk profile. No supplement lowers LDL the way proven therapies do, so bring your results to your doctor before deciding what to do.
From Nuvirox
Why we formulated NAD+ Restore
Whatever your lipid panel shows, every cell in your body, from liver to artery wall, still runs on everyday cellular energy metabolism, the general biology we formulated around. NAD+ is the coenzyme your cells lean on to turn food into usable energy, and levels tend to drift down with age. We formulated NAD+ Restore to support healthy NAD+ levels and everyday cellular energy, built around the approach with the most published human research behind it rather than around hype.
It comes with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
High LDL means more cholesterol-carrying particles are passing through your arteries, and the evidence that this causes heart disease is about as strong as it gets in cardiology. But one number isn't a diagnosis: risk depends on how high, how long, how accurately measured, and what else is going on, including lipoprotein(a) and family history. Confirm the result, rule out secondary causes, and plan with your clinician. If your LDL-C is 190 mg/dL or higher, make that appointment soon.
References
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. DOI: 10.1093/eurheartj/ehx144. PMID: 28444290. PMCID: PMC5837225.
- Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. DOI: 10.1016/S0140-6736(10)61350-5. PMID: 21067804. PMCID: PMC2988224.
- Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578-2589. DOI: 10.1016/j.jacc.2016.03.520. PMID: 27050191. PMCID: PMC5405769.
- Abdullah SM, Defina LF, Leonard D, et al. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation. 2018;138(21):2315-2325. DOI: 10.1161/CIRCULATIONAHA.118.034273. PMID: 30571575.
- Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061-2068. DOI: 10.1001/jama.2013.280532. PMID: 24240933. PMCID: PMC4226221.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143. DOI: 10.1161/CIR.0000000000000625. PMID: 30586774. PMCID: PMC7403606.
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. J Am Coll Cardiol. 2026;87(19):2624-2757. DOI: 10.1016/j.jacc.2025.11.016. PMID: 41824590.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.